A Review of the Recent Monkeypox Outbreak in 2022
Source : https://www.cureus.com/articles/108076-a-review-of-the-recent-monkeypox-outbreak-in-2022/metrics
Published: August 11, 2022 DOI: 10.7759/cureus.27880 Cite this article as: Al-Gburi S, Namuq Z (August 11, 2022) A Review of the Recent Monkeypox Outbreak in 2022. Cureus 14(8): e27880. doi:10.7759/cureus.27880...
This is a comprehensive review of monkeypox virus epidemiology, clinical features, and the most up-to-date, effective management and prevention.
Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, especially in individuals with risk factors.
The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study
Source : https://doi.org/10.3389/fpubh.2022.877944
BackgroundThe cardiovascular complications of Coronavirus Disease 2019 (COVID-19) may be attributed to the hyperinflammatory state leading to increased mortality in patients with COVID-19. HMG-CoA Reductase Inhibitors (statins) are known to...
Conclusion: The use of statin therapy during ICU stay in critically ill patients with COVID-19 may have a beneficial role and survival benefit with a good safety profile.
The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review
Published: August 13, 2022 DOI: 10.7759/cureus.27979 Cite this article as: Thandavaram A, Channar A, Purohit A, et al. (August 13, 2022) The Efficacy of Bezlotoxumab in the Prevention of Recurrent...
In conclusion, bezlotoxumab is a great option adjunctive with standard of care CDI antibiotics for the prevention of rCDI in high-risk adults.
LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.